A comprehensive review of MDMA and GHB: two common club drugs (Q34476901)

2 August 2017

1 reference

MDMA

0 references

title

A comprehensive review of MDMA and GHB: two common club drugs (English)

1 reference

2 August 2017

Teter CJ

1

1 reference

PubMed ID

11765302

2 August 2017

Guthrie SK

series ordinal

2

1 reference

PubMed ID

11765302

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

21

1 reference

2 August 2017

12

1 reference

2 August 2017

1486-1513

1 reference

Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals.

2 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Interactions of amphetamine analogs with human liver CYP2D6

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Ecstasy (MDMA): a review of its possible persistent psychological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Low-dose MDMA ("ecstasy") induces vasopressin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Neurotoxicity of MDMA and related compounds: anatomic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Intracerebroventricular administration of 5,7-dihydroxytryptamine to mice increases both head-twitch response and the number of cortical 5-HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Memory deficits associated with recreational use of "ecstasy" (MDMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Subjective reports on the effects of the MDMA ('ecstasy') experience in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

The psychological and physiological effects of MDMA on normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

An overdose of ecstasy. A role for dantrolene

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Recreational drug misuse: issues for the cardiologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Ecstasy induced acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Pathology of deaths associated with "ecstasy" and "eve" misuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Intracerebral haemorrhage and drug abuse in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Hyponatraemia and catatonic stupor after taking "ecstasy".

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

21 January 2018

Hyponatraemia at a rave

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Hyponatraemia must be treated with low water input

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Cerebral oedema after MDMA ("ecstasy") and unrestricted water intake. Drug workers emphasise that water is not an antidote to drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Acute liver damage and ecstasy ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy')

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

21 January 2018

Ecstasy and dantrolene

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Ecstasy intoxication: appreciation of complications and the role of dantrolene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

The management of cocaine-associated myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

GAMMA-HYDROXYBUTYRATE, A NORMAL BRAIN METABOLITE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

VARIOUS SEIZURE ACTIVITIES FOLLOWING GAMMA-HYDROXYBUTYRATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Slow wave sleep and a state resembling absence epilepsy induced in the rat by γ-hydroxybutyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Pediatric benzodiazepine ingestion resulting in hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Conversion in vivo of γ-aminobutyric to γ-hydroxybutyric acid in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Formation of gamma-hydroxybutyrate in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Developmental time courses in the brain and kidney of two enzymes that oxidize gamma-hydroxybutyrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Metabolism of gamma-hydroxy-[1-14C] butyrate by rat brain: relationship to the Krebs cycle and metabolic compartmentation of amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Function of gamma-hydroxybutyrate: a putative neurotransmitter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma-hydroxybutyrate, a possible neurotransmitter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Significance of gamma-hydroxybutyric acid in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Sites of action of gamma-hydroxybutyrate (GHB)--a neuroactive drug with abuse potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma hydroxybutyrate distribution and turnover rates in discrete brain regions of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

High affinity binding sites for gamma-hydroxybutyric acid in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

gamma-Hydroxybutyrate uptake by rat brain striatal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma-hydroxybutyrate stimulation of the formation of cyclic GMP and inositol phosphates in rat hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

γ-Hydroxybutyrate hyperpolarizes hippocampal neurones by activating GABAB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Failure of gamma-hydroxybutyrate to alter the function of the GABAA receptor complex in the rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Effect of -hydroxybutyrate on the release of monoamines from the rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

The effect of gammahydroxy-butyrate on the H-reflex: Pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

An EEG-behavioral study of sodium hydroxybutyrate in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

ynergy of ethanol and a natural soporific--gamma hydroxybutyrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Continuous sedation during spinal anaesthesia: gamma-hydroxybutyrate vs. propofol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gammahydroxybutyrate: an endogenous regulator of energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Long-term administration of GHB does not affect muscular mass in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous recreational drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma hydroxybutyrate poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma hydroxybutyrate--a coma inducing recreational drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Clinical course of gamma-hydroxybutyrate overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Coma and respiratory depression following the ingestion of GHB and its precursors: three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Physical dependence on sodium oxybate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Severe gamma-hydroxybutyrate withdrawal: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

"Grievous bodily harm:" gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Gamma-hydroxybutyrate associated deaths.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Adverse events, including death, associated with the use of 1,4-butanediol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Coma-inducing drug GHB may be reclassified.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

Fatal interaction between ritonavir and MDMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

21 January 2018

Sodium 4-hydroxybutyrate

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1486.34472

10.1592/PHCO.21.20.1486.34472

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11765302